Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McClellan To Head Medicare Rx Law Implementation: Will Greater FDA/CMS Cooperation Ensue?

This article was originally published in The Pink Sheet Daily

Executive Summary

President Bush nominates FDA Commissioner McClellan to head Centers for Medicare & Medicaid Services Feb. 20. McClellan's closest advisors will remain at FDA, suggesting era of greater cooperation between the two agencies could result.

You may also be interested in...



FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review

A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.

FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review

A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.

Energy & Commerce Committee Closely Monitors First Post-McClellan ODAC Meeting

Rep. Deutsch and Energy & Commerce Committee staffers get first row reserved seat at May 3 Genta’s Genasense and Allos’ Excelar meeting. Meeting serves as the litmus test for concerns that agency review process will “revert” to overregulation by FDA in post-Commissioner McClellan period.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel